lebrikizumab
Selected indexed studies
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (N Engl J Med, 2023) [PMID:36920778]
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. (Br J Dermatol, 2023) [PMID:36994947]
- Lebrikizumab. (, 2006) [PMID:39418403]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (2023) pubmed
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. (2023) pubmed
- Lebrikizumab. (2006) pubmed
- Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy. (2025) pubmed
- Lebrikizumab: First Approval. (2024) pubmed
- Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. (2025) pubmed
- Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab. (2023) pubmed
- Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin). (2025) pubmed
- Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. (2024) pubmed
- Lebrikizumab Rapidly Lowers Inflammatory Biomarkers with Clinical Correlations in Moderate-to-Severe Atopic Dermatitis. (2025) pubmed